Reshaping the HIV treatment and prevention landscape
Improvements in cycle times have been driven by focus, operational excellence gsk
and smart risk taking
Blenrep (BCMA ADC)
-
2H 2018
1H 2019
2H 2019
1H 2020
2H 2020
1H 2021
2H 2021
Approved just over two years after pivotal study
start
Pivotal study
start (Jul)
Pivotal data Submission
(Aug)
(Dec)
Approval
(Aug)
RSV Older Adults
-
Accelerated development to enable potential first-
in-class position
sotrovimab (VIR-7831)
-
Received FDA Emergency Use Authorization 13
months after announcing the deal
otilimab (aGM-CSF)
-
Encouraging Phase 2 data generated for COVID
within 8 months of study start
Ph1/2 start
(Jan)
EUA emergency use authorisation
Ph1/2 data
(May)
Ph3 start
(Feb)
Deal signed
(April)
Ph1 start
(Aug)
Ph3 data FDA EUA
(Mar) (May)
Idea
(Mar)
Ph2 start
(May)
Ph2 data Extension
(Jan) study (Feb)
Extension data
(Q3)
49View entire presentation